EGFR and non-small cell lung carcinoma: In Thailand, a retrospective multicenter study conducted by Sukauichai et al. (2013–2019) reported that the median OS for advanced NSCLC patients treated with EGFR-TKIs was significantly longer compared to those receiving chemotherapy alone (19.08–32.46 months vs. 11.10 months, p = 0.006) [8].